Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
deals
genentech
2
×
life sciences
national blog main
national top stories
new york blog main
san francisco blog main
acetylon pharmaceuticals
ambys medicines
boston
cancer
cancer immunotherapy
cell therapy
center for medicare and medicaid services
companion diagnostic
constellation pharmaceuticals
daniel o'day
fda
foundation medicine
foundationone cdx
foundationone heme
gene therapy
holger willenbring
ipo
jeffrey tong
juan carlos izpisua belmonte
keith dionne
liver disease
markus grompe
martin burke
new york top stories
oregon stem cell center
osimertinib
proteon therapeutics
roche
rucaparib (rubraca)
salk institute for biological studies
What
big
2
×
acquire
agreed
aiming
ambys
billion
biotech
broad
confidence
control
deadly
deal
debuted
didn’t
diseases
formed
foundation
future
gain
genentech
launch
liver
make
medicine
medicines
momentum
morning
new
panels
pay
pays
picked
profiling
recently
redux
remaining
rest
roche
share
startup
Language
Current search:
genentech
×
big
×
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
